Skip to main content

Table 3 Reported data for HAQ CFB, ACR-50 and DAS28 < 2.6 at 24 and 52 weeks

From: Abatacept with methotrexate versus other biologic agents in treatment of patients with active rheumatoid arthritis despite methotrexate: a network meta-analysis

Trial

N

Mean HAQ CFB at 24 weeks (SD)

Mean HAQ CFB at 52 weeks (SD)

ACR-50 r at 24 weeks

ACR-50 r at 52 weeks

DAS28 < 2.6 r at 24 weeks

DAS28 < 2.6 r at 52 weeks

Placebo + MTX

       

AIM [14, 18]

219

-0.40 (0.59)

-0.37 (0.59)

37

40

6

4

Kremer et al. 2005, Kremer et al. 2003 [16, 17]

119

-0.14 (0.49*)

-0.10 (0.83*)

14

24

11

12

ATTEST [15]

110

-0.29 (0.22)

 

22

 

3

 

ARMADA [25]

62

-0.27 (0.57)

 

5

   

DE019 [24]

200

-0.24 (0.52)

-0.25 (0.56)

19

19

  

RAPID I [26, 27, 29]

199

-0.17 (0.56)

-0.18 (0.56)

15

15

  

RAPID II [28, 29]

127

-0.14 (0.45)

 

4

 

1

 

Weinblatt et al. 1999 [32]

30

-0.40 (0.49*)

 

1

   

TEMPO [30, 31]

228

-0.63 (1.08*)

-0.63 (1.41*)

92

91

31

39

GO-FORWARD [33, 34]

133

-0.13 (0.58)

 

18

 

8

 

ATTRACT [35, 36]

88

-0.19 (0.49*)

-0.17 (0.60*)

 

8

  

DANCER [39, 40]

122

-0.28 (0.50)

 

16

   

Strand et al. 2006 [41]

40

-0.40 (0.62*)

-0.30 (0.64*)

5

2

  

SERENE [37, 38]

172

-0.19 (0.56*)

-0.19† (0.60*)

15

15

3

3

OPTION [43, 44]

204

-0.34 (0.83*)

 

22

 

1

 

LITHE [42]

393

   

39

 

12

Abatacept + MTX

       

AIM [14, 18]

433

-0.59 (0.62)

-0.66 (0.62)

173

209

64

103

Kremer et al. 2005, Kremer et al. 2003 [16, 17]

115

-0.42 (0.49*)

-0.47 (0.83*)

42

48

30

40

ATTEST [15]

156

-0.68 (0.22)

-0.67 (0.62)

63

71

18

29

Adalimumab + MTX

       

ARMADA [25]

67

-0.62 (0.63)

 

37

   

DE019 [24]

207

-0.56 (0.52)

-0.59 (0.57)

81

86

  

Certolizumab + MTX

       

RAPID I [26, 27, 29]

393

-0.58 (0.59)

-0.60 (0.59)

146

147

  

RAPID II [28, 29]

246

-0.50 (0.47)

 

80

 

23

 

Etanercept + MTX

       

Weinblatt et al. 1999 [32]

59

-0.70 (0.49*)

 

23

   

TEMPO [30, 31]

231

-0.89 (1.08*)

-0.97 (1.41*)

136

180

70

88

Golimumab + MTX

       

GO-FORWARD [33, 34]

89

-0.47 (0.55)

 

33

 

18

 

Infliximab + MTX

       

ATTEST [15]

165

-0.53 (0.29)

-0.59 (0.64)

61

60

21

20

ATTRACT [35, 36]

86

-0.31 (0.49*)

-0.32 (0.60*)

 

21

  

Rituximab + MTX

       

DANCER [39, 40]

122

-0.49 (0.55)

 

41

   

Strand et al. 2006 [41]

40

-0.60 (0.92*)

-0.60 (0.88*)

17

14

  

SERENE [37, 38]

170

-0.42 (0.54*)

-0.47 (0.60*)

44

61

15

19

Tocilizumab + MTX

       

OPTION [43, 44]

205

-0.55 (0.82*)

 

90

 

47

 

LITHE [42]

398

   

145

 

127

  1. *Standard deviation (SD) was estimated.
  2. †No placebo value was available at 52 weeks for placebo so the values have been assumed equal to the values for 24 weeks.
  3. ABA, abatacept; ADA, adalimumab; CFB, change from baseline; CZP, certolizumab pegol; ETN, etanercept; GOL, golimumab; INF, infliximab; N, number of patients in trial; PBO, placebo; r, number of responders; RTX, rituximab; TCZ, tocilizumab
Back to article page

Arthritis Research & Therapy

ISSN: 1478-6362

Contact us